Advanced Biomed Inc. (ADVB) Stock Price & Analysis
Advanced Biomed Inc. (ADVB) fell 0.69% to USD 9.34 as of September 8, 2026 at 13:23 UTC, according to Nexqual real-time market data.
ADVB last closed at USD 9.34; the session ranged USD 9.1–9.44 on volume of 66,457 shares. Market capitalization is —, with a 52-week range of USD 3.61–24.23 (NCM). Source: Nexqual, September 8, 2026 at 13:23 UTC.
Key Statistics (as of September 8, 2026 at 13:23 UTC)
| Price | USD 9.34 |
|---|---|
| Change | ▼ 0.69% (down) |
| Previous Close | USD 9.34 |
| Open | USD 9.34 |
| Day Range | USD 9.1 – 9.44 |
| 52-Week Range | USD 3.61 – 24.23 |
| Volume | 66,457 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ADVB)
Nexqual's technical model rates ADVB "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 13:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.52 (neutral) |
| vs SMA50 | Above (USD 8.14) |
| MACD | 0.4 (positive) |
From Advanced Biomed Inc.'s Latest SEC 10-K Filing (filed 2025-10-08)
Key Strengths & Strategy (as disclosed to the SEC)
- One injection-type production equipment is expected to produce 50,000 pieces of A + Pre Chip per month.   Our Platform   We have built our microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips.
- In addition, we file for patent protection on our on-going research and development, particularly into early-stage cancer screening.   We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
- Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor technology and biotechnology.
- The parties agree to take the Taiwan Taipei District Court as the jurisdiction court of first instance for any disputes arising from the execution of this agreement, which shall be subject to the laws of Taiwan.   As for the designed microfluidic detector, since 2020, we have developed various functional microfluidic biomedical testing devices for microfluidic modules, automation software, and hardware.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIYA | Baiya International Group Inc. | USD 2.26 | ▲ 3.2% |
| INLF | INLIF LIMITED | USD 3.78 | ▼ 3.32% |
| JEM | 707 Cayman Holdings Limited | USD 4.1 | ▼ 6.82% |
| ZYBT | Zhengye Biotechnology Holding L | USD 1.61 | ▼ 1.23% |
| PAVS | Paranovus Entertainment Technol | USD 4.7 | ▼ 4.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 13:23 UTC. This page is informational and not investment advice.